Seres Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| SERES THERAPEUTICS, INC. | ||
| Date: March 12, 2026 | By: | /s/ Richard N. Kender |
|---|---|---|
| Richard N. Kender | ||
| Executive Chair and Interim Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Richard N. Kender | Executive Chair and Interim Chief Executive Officer (Principal Executive Officer) | March 12, 2026 |
| Richard N. Kender | ||
| /s/ Marella Thorell | Executive Vice President, Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer) | March 12, 2026 |
| Marella Thorell | ||
| /s/ Stephen Berenson | Director | March 12, 2026 |
| Stephen Berenson | ||
| /s/ Dennis A. Ausiello | Director | March 12, 2026 |
| Dennis A. Ausiello, M.D. | ||
| /s/ Rob Rosiello | Director | March 12, 2026 |
| Rob Rosiello | ||
| /s/ Willard H. Dere | Director | March 12, 2026 |
| Willard H. Dere, M.D. | ||
| /s/ Claire M. Fraser | Director | March 12, 2026 |
| Claire M. Fraser, Ph.D. | ||
| /s/ Kurt C. Graves | Director | March 12, 2026 |
| Kurt C. Graves | ||
| /s/ Hans-Juergen Woerle, M.D., Ph.D. | Director | March 12, 2026 |
| Hans-Juergen Woerle, M.D., Ph.D. | ||
| /s/ Eric D. Shaff | Director | March 12, 2026 |
|---|---|---|
| Eric D. Shaff | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID 238) | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | F-4 |
| Consolidated Statements of Operations and Comprehensive Income (Loss) for the years ended December 31, 2025, 2024 and 2023 | F-5 |
| Consolidated Statements of Stockholders’ Equity (Deficit) as of December 31, 2025, 2024 and 2023 | F-6 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2025, 2024 and 2022 | F-7 |
| Notes to Consolidated Financial Statements | F-9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.